The future of medicine lies within us.
We develop one-time in vivo treatments that precisely engineer any cell of the hematopoietic system to cure diseases from within.
Through the Engenious™ platform, Ensoma is pioneering a therapeutic approach with unprecedented scope for tackling diseases that affect millions around the world, including cancer and autoimmune disease as well as inherited conditions.
Engenious combines innovative delivery technology with the full DNA editing toolkit in a single platform. For the first time, we can precisely engineer any combination of immune cells with complex functionality. That means smarter cells for curative therapies.
Ensoma is supported by top-tier investors and a strategic collaboration with Takeda.